Christopher Glezos, MD
Orthopaedic Surgery · Fresno, CANPI 1922341601
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,456 of the $39,029 with a category attached, or 90.8%. Medical Device Business Services, Inc. accounts for 96.0% of it on its own, with 9 other manufacturers making up the rest.
Across 66 payments — averaging $591.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$37K
- Johnson & Johnson$871
- Stryker$428
- Urgo Medical North America, LLC$100
- Heraeus Medical, LLC.$47
- Smith+Nephew$32
- plus $83 from 4 others
Across 2 payments — averaging $37,500 each. An ownership or investment interest held by the physician or an immediate family member.
- Lazurite Inc.$75K
What the payments were for
- Consulting fees$35,45691%
- Travel & lodging$1,1333%
- Food & beverage$2,4406%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 35 | $37,469 |
| Johnson & Johnson(2 entities) | 11 | $871 |
| Stryker | 10 | $428 |
| Urgo Medical North America, LLC | 1 | $100 |
| Heraeus Medical, LLC. | 2 | $47 |
| Smith+Nephew | 2 | $32 |
| Omnilife Science, Inc | 2 | $31 |
| Amgen | 1 | $20 |
| BD | 1 | $17 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,029 in reported general payments places this provider in the 85th percentile of 1,808 orthopaedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 122 | $4,528 |
| Gabapentin | 156 | $1,125 |
| Cefadroxil | 118 | $989 |
| Oxycodone Hcl | 131 | $951 |
| Meloxicam | 101 | $330 |
| Tramadol Hcl | 22 | $56 |
| Amoxicillin | 28 | $27 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Fresno
- Connor TellesFresno$1M
- Julia LeeFresno$458K
- Bradford HackArcadia$18.3M
- Robert GorabOrange$13.6M
- Kelly VinceLos Angeles$9.6M
- Stephen HowellSacramento$9.4M
- Thomas CoonRed Bluff$9.2M
- Nirav AminPlacentia$5.6M
- Tom NorrisSan Francisco$5.3M
- Jay LiebermanLos Angeles$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.